Bank of New York Mellon’s Adverum Biotechnologies ADVM Stock Holding History

Bank of New York Mellon’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-49,324	Closed	-$216K	–	4140
2025 Q1	$216K	Buy	49,324 +989	+2%	+$4.46K	﹤0.01%	3858
2024 Q4	$226K	Hold	48,335	–	–	﹤0.01%	3907
2024 Q3	$339K	Sell	48,335 -16,250	-25%	-$118K	﹤0.01%	3701
2024 Q2	$443K	Buy	+64,585	New	+$601K	﹤0.01%	3641
2024 Q1	–	Sell	-3,961	Closed	-$29.8K	–	4153
2023 Q4	$29.8K	Sell	3,961 -2,877	-42%	-$26.3K	﹤0.01%	4200
2023 Q3	$103K	Sell	6,838 -78	-1%	-$1.4K	﹤0.01%	4076
2023 Q2	$110K	Buy	6,916 +1,467	+27%	+$15.4K	﹤0.01%	4074
2023 Q1	$39.1K	Hold	5,449	–	–	﹤0.01%	4235
2022 Q4	$31.6K	Sell	5,449 -11	-0.2%	-$83	﹤0.01%	4299
2022 Q3	$52K	Sell	5,460 -1,511	-22%	-$19.9K	﹤0.01%	4317
2022 Q2	$84K	Sell	6,971 -25,348	-78%	-$266K	﹤0.01%	4264
2022 Q1	$424K	Sell	32,319 -406	-1%	-$5.94K	﹤0.01%	3812
2021 Q4	$576K	Buy	32,725 +475	+1%	+$9.51K	﹤0.01%	3712
2021 Q3	$700K	Buy	32,250 +1,647	+5%	+$42K	﹤0.01%	3614
2021 Q2	$1.07M	Sell	30,603 -1,649	-5%	-$88.8K	﹤0.01%	3368
2021 Q1	$3.18M	Sell	32,252 -1,542	-5%	-$185K	﹤0.01%	2659
2020 Q4	$3.66M	Buy	33,794 +586	+2%	+$72.5K	﹤0.01%	2507
2020 Q3	$3.42M	Buy	33,208 +431	+1%	+$64.5K	﹤0.01%	2413
2020 Q2	$6.84M	Buy	32,777 +6,907	+27%	+$1.22M	﹤0.01%	2051
2020 Q1	$2.53M	Buy	25,870 +2,001	+8%	+$233K	﹤0.01%	2436
2019 Q4	$2.75M	Buy	23,869 +4,629	+24%	+$408K	﹤0.01%	2630
2019 Q3	$1.05M	Sell	19,240 -6,780	-26%	-$764K	﹤0.01%	3156
2019 Q2	$3.09M	Buy	26,020 +4,237	+19%	+$351K	﹤0.01%	2568
2019 Q1	$1.14M	Sell	21,783 -8	-0%	-$323	﹤0.01%	3086
2018 Q4	$686K	Sell	21,791 -187	-0.9%	-$7.61K	﹤0.01%	3315
2018 Q3	$1.33M	Buy	21,978 +3,318	+18%	+$186K	﹤0.01%	3090
2018 Q2	$989K	Buy	18,660 +13,471	+260%	+$810K	﹤0.01%	3247
2018 Q1	$301K	Buy	5,189 +1,100	+27%	+$68.5K	﹤0.01%	3796
2017 Q4	$143K	Buy	4,089 +218	+6%	+$7.17K	﹤0.01%	4017
2017 Q3	$141K	Hold	3,871	–	–	﹤0.01%	3937
2017 Q2	$97K	Sell	3,871 -3,357	-46%	-$91.8K	﹤0.01%	4033
2017 Q1	$196K	Sell	7,228 -28	-0.4%	-$796	﹤0.01%	3885
2016 Q4	$211K	Buy	7,256 +521	+8%	+$17K	﹤0.01%	3883
2016 Q3	$277K	Buy	6,735 +663	+11%	+$25.2K	﹤0.01%	3789
2016 Q2	$192K	Buy	6,072 +206	+4%	+$9.31K	﹤0.01%	3911
2016 Q1	$303K	Sell	5,866 -617	-10%	-$34.5K	﹤0.01%	3641
2015 Q4	$618K	Sell	6,483 -2,299	-26%	-$202K	﹤0.01%	3429
2015 Q3	$723K	Buy	8,782 +1,004	+13%	+$128K	﹤0.01%	3383
2015 Q2	$1.26M	Buy	7,778 +2,813	+57%	+$949K	﹤0.01%	3205
2015 Q1	$2.01M	Buy	4,965 +1,601	+48%	+$677K	﹤0.01%	2858
2014 Q4	$1.82M	Buy	3,364 +1,119	+50%	+$431K	﹤0.01%	2931
2014 Q3	$767K	Buy	+2,245	New	+$668K	﹤0.01%	3438

Other funds holding ADVM

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

PWA

Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of New York Mellon's ADVM Position: Q2 2025 in Review

Bank of New York Mellon sold out of Adverum Biotechnologies (ADVM) in Q2 2025, closing a stake of 49,324 shares — an estimated $216K sold.

Bank of New York Mellon first reported a position in ADVM in Q3 2014 and held it in 42 quarters. The position peaked at $6.84M in Q2 2020. 58 funds tracked by Wall St. Rank hold ADVM as of Q2 2025.

Bank of New York Mellon reported no remaining Adverum Biotechnologies position as of Q2 2025 after selling out during the quarter.
Bank of New York Mellon sold 49,324 Adverum Biotechnologies shares in Q2 2025, an estimated $216K.
Bank of New York Mellon first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 42 quarters.
Bank of New York Mellon's Adverum Biotechnologies position peaked at $6.84M in Q2 2020.
58 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2025.

Based on Bank of New York Mellon's 13F filing for Q2 2025, filed 5 Aug 2025.